Neuronetics, Inc. (STIM) Research

Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.

Market snapshot

Symbol
STIM
Price
$1.23
Day change
+1.65%
Market cap
$85.6M
P/E ratio
-2.31x
52-week range
0.8-4.85
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months
Analyst price target
$8.00

Peer companies

  • Atlantic International Corp. (ATLN)
  • Perspective Therapeutics, Inc. (CATX)
  • Codexis, Inc. (CDXS)
  • Genfit S.A. (GNFT)
  • Nyxoah S.A. (NYXH)
  • OmniAb, Inc. (OABI)
  • OraSure Technologies, Inc. (OSUR)
  • Prenetics Global Limited (PRE)

Recent insider activity

  • Amin Avinash — J-Other (2934 shares) on 2026-06-15
  • Amin Avinash — J-Other (34932 shares) on 2026-06-15
  • Amin Avinash — J-Other (4634 shares) on 2026-06-15
  • Madryn Asset Management, LP — J-Other (34932 shares) on 2026-06-15
  • Madryn Asset Management, LP — J-Other (24658 shares) on 2026-05-28

Open Neuronetics, Inc. (STIM) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.